|
|
|
SEPTEMBER'S BEST FEATURED EDITORIAL
|
|
|
|
|
|
By Devan Shah
|
Merck and Moderna's Phase 3 results in melanoma offer the strongest validation yet for personalized cancer vaccines, writes Devan Shah.
|
|
|
|
|
|
SEPTEMBER'S BEST INDUSTRY INSIGHTS
|
|
|
|
|
|
|
|
|
|
BCVA, OCT, And IOP Testing In Clinical Trials
|
Are minor inconsistencies in room setup and technician technique quietly compromising your study data? Learn how closing small operational gaps can prevent major downstream risks.
|
|
|
| Connect With Life Science Leader: |
|
|
|
|
